Short Interest in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Increases By 25.6%

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRXGet Rating) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totalling 176,000 shares, a growth of 25.6% from the June 30th total of 140,100 shares. Based on an average trading volume of 532,400 shares, the short-interest ratio is presently 0.3 days. Approximately 1.4% of the company’s stock are sold short.

Institutional Trading of Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Renaissance Technologies LLC bought a new position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRXGet Rating) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 93,619 shares of the company’s stock, valued at approximately $58,000. Renaissance Technologies LLC owned approximately 0.74% of Kiora Pharmaceuticals at the end of the most recent quarter. 29.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KPRX. Maxim Group decreased their target price on Kiora Pharmaceuticals to $1.00 in a research report on Thursday, May 26th. HC Wainwright reduced their price objective on Kiora Pharmaceuticals from $3.00 to $2.50 and set a “buy” rating for the company in a research report on Monday, July 11th.

Kiora Pharmaceuticals Price Performance

KPRX stock opened at $0.15 on Tuesday. Kiora Pharmaceuticals has a twelve month low of $0.14 and a twelve month high of $2.80. The firm has a market cap of $1.95 million, a PE ratio of -0.09 and a beta of 0.43. The business has a 50 day moving average of $0.36 and a 200 day moving average of $0.52.

Kiora Pharmaceuticals (NASDAQ:KPRXGet Rating) last posted its quarterly earnings data on Friday, July 8th. The company reported ($0.27) earnings per share for the quarter. On average, research analysts expect that Kiora Pharmaceuticals will post -0.57 earnings per share for the current fiscal year.

About Kiora Pharmaceuticals

(Get Rating)

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with's FREE daily email newsletter.